Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 8:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Rett Syndrome
Interventions: dextromethorphan, placebo; Drug
Lead sponsor: Hugo W. Moser Research Institute at Kennedy Krieger, Inc.; Other
Eligibility: 1 Year to 10 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Chronic Kidney Disease
Interventions: Lower Dose Sodium Bicarbonate, Higher Dose Sodium Bicarbonate, Placebo; Drug
Lead sponsor: Jennifer Gassman, PhD; Other
Eligibility: 18 Years and older
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 7
States / cities: Denver, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 3 more

Conditions: Intermittent Hypoxia
Interventions: Caffeine, Placebos; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 32 Weeks to 36 Weeks
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 15
States / cities: Loma Linda, California • Washington D.C., District of Columbia • Orlando, Florida + 11 more

Conditions: Tinnitus
Interventions: incobotulinum toxin A, Placebo-Saline; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain
Interventions: Ibuprofen Sodium, Standard Ibuprofen, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Miscarriage, Recurrent, Abortion, Habitual
Interventions: Gamimune N or Gamunex 10%, normal saline; Biological · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2010
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Potassium chloride powder, Potassium magnesium Citrate (KMgCit), Potassium citrate powder, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 21 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dementia With Lewy Bodies
Interventions: Placebo, 192 mg powder of K0706, 384 mg powder of K0706; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 25 Years to 90 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Cardiovascular Diseases
Interventions: Empagliflozin, Placebos; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Essential Tremor, Deep Brain Stimulation
Interventions: Alternating stimulation, Placebo; Other
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Myasthenic Syndromes, Congenital
Interventions: amifampridine phosphate, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Alcohol Abuse
Interventions: Protandim; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 21 Years to 55 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Pain Related to TMD
Interventions: THOR® laser system, sham THOR® laser system; Device
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 65 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Type 2 Diabetes, End Stage Renal Disease on Dialysis
Interventions: Semaglutide, Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Dallas, Texas • Irving, Texas

Conditions: Child Development, Prenatal Stress
Interventions: Choline, Placebo; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2025
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Opioid Use Disorder, Alcohol Intoxication, Pain
Interventions: Alcohol, Placebo; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 21 Years to 65 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Adolescent Idiopathic Scoliosis
Interventions: AbobotulinumtoxinA, Placebos, Custom Thoracolumbosacral Orthosis; Drug · Device
Lead sponsor: Johns Hopkins University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Aging, Vascular Stiffness, Vascular Dilation
Interventions: Calcium Acetate Oral Solution, Calcium Carbonate Oral Suspension; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 50 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Major Depressive Disorder
Interventions: Valganciclovir, Placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Tulsa, Oklahoma

Conditions: Neonatal Encephalopathy, Birth Asphyxia
Interventions: Normal saline placebo, Erythropoietin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 24 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Idiopathic Hypersomnia
Interventions: Open-label Pitolisant, Double-blind Placebo, Double-blind Pitolisant; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 58
States / cities: Peoria, Arizona • Scottsdale, Arizona • Los Angeles, California + 53 more

Conditions: High Risk MSM, HIV Negative, 18-30 Years of Age
Interventions: HEC Placebo Gel, Tenofovir 1% Gel; Other · Drug
Lead sponsor: CONRAD; Other
Eligibility: 18 Years to 30 Years · Male only
Enrollment: 249 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Boston, Massachusetts • Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Tocilizumab (TCZ), Methotrexate (MTX), Placebo (PBO); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 718 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 155
States / cities: Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 126 more

Conditions: Migraine Disorders, Migraine, Acute
Interventions: TREXIMET®, Butalbital-containing Combination Medications (BCM), placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 107
States / cities: Chandler, Arizona • Gilbert, Arizona • Litchfield Park, Arizona + 94 more

Search by objective public record fields.

Placebo Controlled Trial of Dextromethorphan in Rett Syndrome

The BASE Study: Bicarbonate Administration to Stabilize Estimated Glomerular Filtration Rate (eGFR)

Intermittent Hypoxia and Caffeine in Infants Born Preterm

The Efficacy of Incobotulinum Toxin A Injections for Treatment of Tinnitus: a Randomized Controlled Trial

Ibuprofen Sodium Tension Headache Study

Intravenous Immunoglobulin (IVIG) for Treatment of Unexplained Secondary Recurrent Miscarriage

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

K0706 for Patients Diagnosed With Dementia With Lewy Bodies

Are the "Cardiac Benefits" of Empagliflozin Independent of Its Hypoglycemic Activity? (ATRU-4).

The Effectiveness of Alternating Stimulation in Preventing Tolerance in Essential Tremor Patients

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Antioxidant Replacement Therapy in Patients With Alcohol Abuse

Photobiomodulation for the Management of Temporomandibular Disorder Pain

DIALYSIS-TIR Study

Choline Supplementation During Pregnancy: Impact on Attention and Social Withdrawal

Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals With Opioid Use Disorder

Dysport ® as an Adjunctive Treatment to Bracing in the Management of Adolescent Idiopathic Scoliosis

Acetate and Age-associated Arterial Dysfunction

ANTIVIRAL TREATMENT OF CYTOMEGALOVIRUS IN DEPRESSION

High-dose Erythropoietin for Asphyxia and Encephalopathy

A Phase 3 Study to Assess the Safety and Efficacy of Pitolisant in Adult Patients With Idiopathic Hypersomnia

Microbicide Safety and Acceptability in Young Men

A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX

TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults